Antisoma plc

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 02/08/11 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) announces its interim financial information for the period ended 31 December 2010. Announced today * Steps initiated to find a transaction that maximises value of cash and assets * Company will by 31 ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 12/02/10 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) today provides an update on its blood cancer programmes and announces details of a presentation at the American Society of Hematology (ASH) Annual Meeting. AS1413 phase III data in secondary AML expected Q1 2011 Antisoma announced this week that it expects ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 11/30/10 -- During its presentation today at the Piper Jaffray conference, Antisoma plc (LSE: ASM; USOTC: ATSMY) will announce that it now expects to report pivotal data for its cancer drug AS1413 (amonafide L-malate) in the first quarter of 2011. Previous guidance was that the ACCEDE phase III trial, ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 11/24/10 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Chief Executive Officer, Glyn Edwards, will present at the Piper Jaffray 22nd Annual Health Care Conference in New York City, on Tuesday, November 30th at 1.30 pm EST/ 6.30 pm GMT. An audio webcast will be ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 11/11/10 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that a scheduled interim analysis showed that the ATTRACT- 2 trial should stop as ASA404 was unlikely to provide any benefit as a second-line treatment for non-small cell lung cancer. Glyn Edwards, CEO of Antisoma, said: "The findings from ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 11/08/10 -- Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that the Company's US subsidiary, Antisoma, Inc., has received a grant of USD 244,000 under the U.S. Government's Qualifying Therapeutic Discovery Project, a programme created as part of the Patient Protection and Affordable Care Act of ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 10/13/10 -- Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today publishes its Interim Management Statement for the period from 1 July to 12 October 2010. Antisoma's CEO, Glyn Edwards, said: "We are on track to report pivotal trial results for AS1413 in the first half of ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 09/08/10 -- Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that the ACCEDE phase III trial of AS1413 (amonafide L-malate) in secondary acute myeloid leukaemia (secondary AML) is now fully enrolled. Data from the trial are expected in the first half of 2011, with filings for marketing ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 06/21/10 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its CEO, Glyn Edwards, will present at the 5(th) Annual Piper Jaffray Europe Healthcare Conference in London at 1.30 pm local time (08.30 am Eastern time) on Wednesday 23 June. A webcast of the presentation will be available ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 05/17/10 -- Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today publishes its Interim Management Statement for the period from 1 January to 16 May 2010. Antisoma's CEO, Glyn Edwards, said: "We have two promising cancer drugs, AS1413 and AS1411, both of which we expect to report key ... read more

LONDON, UK -- (Marketwire) -- 04/19/10 -- London, UK, Cambridge, MA, and Washington, DC: 19 April 2010 - Antisoma plc (LSE: ASM; USOTC:ATSMY) announces that its scientists and collaborators are presenting six posters on AS1413 (amonafide L-malate) and AS1411 this week at the ... read more

LONDON, UK -- (Marketwire) -- 03/29/10 -- 29 March 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that the planned interim analysis of data from the ATTRACT-1 phase III trial of ASA404 in previously untreated non-small cell lung cancer (NSCLC) has shown that continuation of the trial would be futile, as ... read more

LONDON, UK -- (Marketwire) -- 03/18/10 -- London, UK, and Cambridge, MA: 18 March 2010 - Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that it has started a randomised, controlled, multi-territory, phase IIb trial of AS1411 in patients with acute myeloid leukaemia (AML). Dr Ursula Ney, Chief Operating Officer of Antisoma, said: "AML is a devastating disease ... read more

LONDON, UK -- (Marketwire) -- 02/18/10 -- London, UK, and Cambridge, MA: 18 February 2010 Antisoma plc (LSE: ASM; USOTC: ATSMY) announces its interim financial information for the period ended 31 December 2009. Highlights Potential blockbuster ASA404 advancing with Novartis * Enrolment completed in first-line lung cancer phase III trial * First-line lung ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 02/02/10 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that Daniel Elger, VP Marketing & Communications, will present an overview of the Company's strategy, programmes and prospects at the 12th Annual BIO CEO & Investor Conference in New York on Monday, 8th February at 8:30am EST/1:30pm GMT. A ... read more

LONDON and CAMBRIDGE, MA, and NEW ORLEANS, LA -- (Marketwire) -- 12/07/09 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that positive final data from a phase II trial of AS1413 in patients with secondary acute myeloid leukaemia (secondary AML) were presented this weekend at the American Society of Hematology (ASH) meeting in ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 11/10/09 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) holds its AGM today and provides an update, which also serves as the Company's Interim Management Statement for the period from 1 July 2009 to 9 November 2009. Antisoma's CEO Glyn Edwards, said: "We are finishing 2009 in ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 10/13/09 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its aptamer drug AS1411 has been granted orphan drug status in both the United States and the European Union for the treatment of acute myeloid leukaemia (AML). The grants will provide seven years of market exclusivity in ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 10/09/09 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Annual Report and Accounts for the year ended 30 June 2009 are available to view on the Company's website at www.antisoma.com. The Antisoma Annual Report and Accounts will also be available for inspection at the UK ... read more

LONDON and CAMBRIDGE, MA -- (Marketwire) -- 09/18/09 -- Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Chief Executive Officer, Glyn Edwards, will present an overview of the Company's strategy, programmes and prospects at the UBS Global Life Sciences Conference in New York in New York City, on Wednesday, September 23rd at ... read more